Lung Cancer Clinical Trials in Baltimore

Showing 701-720 of 722 trials

Laboratory Test in Predicting Response to Erlotinib in Patients With Relapsed Metastatic or Unresectable Non-Small Cell Lung Cancer That Did Not Respond to Previous Treatment

NCT00673569

RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer. It may also help doctors learn how well patients will respond to treatment. PURPOSE: This phase II trial is studying how well a laboratory test predicts response to erlotinib in patients with metastatic or unresectable non-small cell lung cancer that did not respond to previous treatment.

Lung Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins40 participantsStarted Sep 2006

Baltimore, Maryland, United States

COMPLETEDPhase 2< 1 mile

Study Comparing Amrubicin Versus Topotecan in Patients With Small Cell Lung Cancer Who Have Responded to Prior Therapy.

NCT00319969

The purpose of the study is to evaluate the objective tumor response rate of amrubicin or standard topotecan therapy when administered as second-line therapy to ED-SCLC patients who have chemotherapy sensitive recurrent or progressive.

Small Cell Lung Cancer

Celgene Corporation76 participantsStarted Apr 2006

Birmingham, Alabama, United States • Phoenix, Arizona, United States • Berkeley, California, United States +44 more locations

Laboratory Test in Predicting Response to Erlotinib in Patients With Relapsed Metastatic or Unresectable Non-Small Cell Lung Cancer That Did Not Respond to Previous Treatment

Study Comparing Amrubicin Versus Topotecan in Patients With Small Cell Lung Cancer Who Have Responded to Prior Therapy.

Lung Cancer Trials in Other Cities

STA-4783 in Combination With Paclitaxel and Carboplatin for the Treatment of Chemotherapy Naive Patients With Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)

Transitoriness in Cancer Patients, Psychosocial Issues in Cancer Care

Vinorelbine and XR9576 to Treat Cancer

A Study Of SU011248 As Therapy In Patients With Locally Advanced Or Metastatic Non-Small Cell Lung Cancer

Picoplatin as Second-Line Therapy for Patients With Small Cell Lung Cancer

Ispinesib In Patients With Advanced Or Metastatic Non-Small Cell Lung Cancer

Carboplatin Plus Cetuximab for Treatment of Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)

BBR 3464 in Treating Patients With Metastatic Small Cell Lung Cancer That Has Not Responded to Previous Treatment

Phase 2 Study of VELCADE Alone or VELCADE® Plus Docetaxel in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer

Lung Cancer Informational Study (LCIS)

Oral NRX 194204 Study in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Study Tests The Safety And Effectiveness Of SU011248 In Patients With Non-Small Cell Lung Cancer Having Brain Metastases

Bortezomib (Velcade) + Pemetrexed (Alimta) in Advanced NSCLC

Safety Study of XL999 in Adults With Non-Small-Cell Lung Cancer

Study of AT-101 in Combination With Topotecan in Relapsed/Refractory Small Cell Lung Cancer

A Randomized Phase 2 Study of AT-101 in Combination With Docetaxel in Relapsed/Refractory Non-Small Cell Lung Cancer

Study of Motexafin Gadolinium (MGd) for Second Line Treatment of Non-Small-Cell Lung Cancer

Evaluation of the Overall Survival of Meclinertant Versus Placebo After a First Line Chemotherapy With Cisplatin + Etoposide

Other Conditions in Baltimore